EMA: May Consultations Will Address Lingering Concerns With Transparency Plan

Drug Industry Daily
A A
The European Medicines Agency is planning a series of May meetings with industry to unveil the process it plans to use to determine whether clinical trial data is considered confidential under its new transparency rules or whether it must be disclosed.

To View This Article:

Login

Subscribe To Drug Industry Daily